DRD1

D(1A) dopamine receptor · P21728 · DRD1 on Sugi Atlas →

316,910 patent compounds predicted against DRD1, 222,285 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Fenoldopam (SCHEMBL34250)	1.00	16/20
Prochlorperazine (SCHEMBL18429)	1.00	6/20
Methylpromazine (SCHEMBL18993)	1.00	6/20
Methylpromazine (SCHEMBL18994)	1.00	6/20
Prochlorperazine (SCHEMBL40755)	0.82	6/20
Prochlorperazine (SCHEMBL40756)	0.82	6/20
SCHEMBL10247	0.34	6/20
Ketotifen (SCHEMBL4436)	1.00	5/20
Promethazine (SCHEMBL4700)	1.00	5/20
Chlorpromazine (SCHEMBL8321)	1.00	5/20
Ketotifen (SCHEMBL8809)	1.00	5/20
Ketotifen (SCHEMBL8810)	1.00	5/20
Bromocriptine (SCHEMBL25297)	1.00	5/20
Levomepromazine (SCHEMBL25462)	1.00	5/20
Promethazine (SCHEMBL26777)	1.00	5/20
Olanzapine (SCHEMBL28763)	1.00	5/20
Thiothixene (SCHEMBL34305)	1.00	5/20
Trimipramine (SCHEMBL35144)	1.00	5/20
Thiothixene (SCHEMBL40977)	0.96	5/20
Bromocriptine (SCHEMBL40559)	0.96	5/20

Clinical trials — most relevant to DRD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)	PHASE4	COMPLETED
Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD	PHASE4	UNKNOWN
Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder	PHASE4	UNKNOWN
Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease	PHASE4	COMPLETED
A New Pharmacotherapy for Alcohol Dependence: Olanzapine	PHASE3	COMPLETED
New Treatment for Alcohol and Nicotine Dependence	PHASE2/PHASE3	COMPLETED
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM	PHASE3	COMPLETED
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement	PHASE2	COMPLETED
Psychopharmacology for Cocaine Dependence - Buspirone	PHASE2	COMPLETED
Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET	PHASE1/PHASE2	COMPLETED
Dopaminergic Dysfunction in Late-Life Depression	PHASE2	COMPLETED
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder	PHASE2	UNKNOWN
Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112	PHASE1	COMPLETED
Brain Dopaminergic Signaling in Opioid Use Disorders	EARLY_PHASE1	COMPLETED
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders	EARLY_PHASE1	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography	nan	COMPLETED
A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality	nan	SUSPENDED
Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios	nan	COMPLETED
Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia	nan	COMPLETED
A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations	nan	UNKNOWN
Attention Deficit Hyperactivity Disorder: Nutrition and Environment	nan	UNKNOWN
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Dopamine and Insulin Resistance	nan	COMPLETED
The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED
The Genetic Basis for Vulnerability to Substance Abuse	nan	COMPLETED
An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD	nan	COMPLETED
Dopamine Effect on Inhibitory Control	nan	COMPLETED
Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DRD1 binder may also engage these)

Protein	Name	Similarity
P18901	—	1.000	P18901 →
Q95136	—	1.000	Q95136 →
P50130	—	1.000	P50130 →
P42288	—	1.000	P42288 →
O77680	—	1.000	O77680 →
Q61616	—	1.000	Q61616 →
P42289	—	1.000	P42289 →
Q16950	—	1.000	Q16950 →
P53452	—	1.000	P53452 →
O42384	—	1.000	O42384 →
P42290	—	1.000	P42290 →
O73810	—	0.999	O73810 →
Q91081	—	0.998	Q91081 →
Q19084	—	0.998	Q19084 →
O70528	—	0.998	O70528 →
DRD2	D(2) dopamine receptor	0.998	landscape →
P42291	—	0.998	P42291 →
HTR4	5-hydroxytryptamine receptor 4	0.997	landscape →
P52702	—	0.997	P52702 →
O42385	—	0.997	O42385 →
P60026	—	0.997	P60026 →
P97288	—	0.996	P97288 →
P53453	—	0.996	P53453 →
Q25322	—	0.996	Q25322 →
Q62758	—	0.996	Q62758 →
O02213	—	0.996	O02213 →
P79748	—	0.995	P79748 →
P10608	—	0.995	P10608 →
Q91175	—	0.995	Q91175 →
DRD5	D(1B) dopamine receptor	0.995	landscape →